Galmed Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Galmed Pharmaceuticals has been growing earnings at an average annual rate of 21.5%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
21.5%
Earnings growth rate
29.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -34.3% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
May 16
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Jan 06Galmed GAAP EPS of -$0.15 beats by $0.09
Aug 04Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky
May 03Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Jan 15Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
Oct 02Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?
May 20Galmed gets greenlight for late-stage Aramchol NASH trial in China
May 03What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?
Feb 04
We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth
Dec 06Galmed EPS misses by $0.02
Nov 12Revenue & Expenses Breakdown
How Galmed Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -6 | 4 | 3 |
| 30 Jun 24 | 0 | -6 | 3 | 3 |
| 31 Mar 24 | 0 | -6 | 4 | 3 |
| 31 Dec 23 | 0 | -7 | 4 | 4 |
| 30 Sep 23 | 0 | -8 | 4 | 4 |
| 30 Jun 23 | 0 | -11 | 4 | 8 |
| 31 Mar 23 | 0 | -14 | 4 | 9 |
| 31 Dec 22 | 0 | -18 | 5 | 13 |
| 30 Sep 22 | 0 | -23 | 5 | 18 |
| 30 Jun 22 | 0 | -25 | 5 | 20 |
| 31 Mar 22 | 0 | -30 | 5 | 25 |
| 31 Dec 21 | 0 | -32 | 6 | 27 |
| 30 Sep 21 | 0 | -35 | 6 | 30 |
| 30 Jun 21 | 0 | -34 | 5 | 30 |
| 31 Mar 21 | 0 | -32 | 5 | 28 |
| 31 Dec 20 | 0 | -29 | 4 | 26 |
| 30 Sep 20 | 0 | -27 | 4 | 24 |
| 30 Jun 20 | 0 | -24 | 4 | 22 |
| 31 Mar 20 | 0 | -23 | 4 | 20 |
| 31 Dec 19 | 0 | -20 | 4 | 18 |
| 30 Sep 19 | 0 | -16 | 4 | 14 |
| 30 Jun 19 | 2 | -12 | 4 | 11 |
| 31 Mar 19 | 2 | -11 | 4 | 10 |
| 31 Dec 18 | 2 | -10 | 4 | 8 |
| 30 Sep 18 | 2 | -10 | 5 | 8 |
| 30 Jun 18 | 1 | -12 | 4 | 8 |
| 31 Mar 18 | 1 | -12 | 4 | 9 |
| 31 Dec 17 | 1 | -12 | 4 | 10 |
| 30 Sep 17 | 1 | -13 | 3 | 12 |
| 30 Jun 17 | 1 | -15 | 3 | 13 |
| 31 Mar 17 | 1 | -16 | 3 | 14 |
| 31 Dec 16 | 0 | -17 | 3 | 14 |
| 30 Sep 16 | 0 | -15 | 3 | 13 |
| 30 Jun 16 | 0 | -14 | 3 | 11 |
| 31 Mar 16 | 0 | -12 | 3 | 10 |
| 31 Dec 15 | 0 | -11 | 3 | 8 |
| 30 Sep 15 | 0 | -9 | 4 | 6 |
| 30 Jun 15 | 0 | -10 | 3 | 7 |
| 31 Mar 15 | 0 | -9 | 3 | 7 |
| 31 Dec 14 | 0 | -9 | 2 | 7 |
| 30 Sep 14 | 0 | -22 | 9 | 11 |
| 30 Jun 14 | 0 | -20 | 8 | 9 |
Quality Earnings: GLMD is currently unprofitable.
Growing Profit Margin: GLMD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GLMD is unprofitable, but has reduced losses over the past 5 years at a rate of 21.5% per year.
Accelerating Growth: Unable to compare GLMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GLMD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).
Return on Equity
High ROE: GLMD has a negative Return on Equity (-34.3%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 06:29 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Galmed Pharmaceuticals Ltd. is covered by 14 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Edward Nash | Canaccord Genuity |
| Elemer Piros | Cantor Fitzgerald & Co. |